275 related articles for article (PubMed ID: 29338448)
1. The safety of palbociclib for the treatment of advanced breast cancer.
Degenhardt T; Wuerstlein R; Eggersmann T; Harbeck N
Expert Opin Drug Saf; 2018 Mar; 17(3):325-330. PubMed ID: 29338448
[TBL] [Abstract][Full Text] [Related]
2. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
[TBL] [Abstract][Full Text] [Related]
3. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
Mayer EL; DeMichele A; Rugo HS; Miller K; Waks AG; Come SE; Mulvey T; Jeselsohn R; Overmoyer B; Guo H; Barry WT; Huang Bartlett C; Koehler M; Winer EP; Burstein HJ
Ann Oncol; 2019 Sep; 30(9):1514-1520. PubMed ID: 31250880
[TBL] [Abstract][Full Text] [Related]
4. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
Turner NC; Slamon DJ; Ro J; Bondarenko I; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; André F; Puyana Theall K; Huang X; Giorgetti C; Huang Bartlett C; Cristofanilli M
N Engl J Med; 2018 Nov; 379(20):1926-1936. PubMed ID: 30345905
[TBL] [Abstract][Full Text] [Related]
5. Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Pritchard KI; Chia SK; Simmons C; McLeod D; Paterson A; Provencher L; Rayson D
Oncologist; 2017 Jan; 22(1):12-24. PubMed ID: 27864574
[TBL] [Abstract][Full Text] [Related]
6. Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer.
Schickli MA; Berger MJ; Lustberg M; Palettas M; Vargo CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1374-1380. PubMed ID: 30134767
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment.
Dhakal A; Matthews CM; Levine EG; Salerno KE; Zhang F; Takabe K; Early AP; Edge SB; O'Connor T; Khoury T; Young JS; Opyrchal M
Clin Breast Cancer; 2018 Dec; 18(6):e1401-e1405. PubMed ID: 29778787
[TBL] [Abstract][Full Text] [Related]
9. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.
Harbeck N; Iyer S; Turner N; Cristofanilli M; Ro J; André F; Loi S; Verma S; Iwata H; Bhattacharyya H; Puyana Theall K; Bartlett CH; Loibl S
Ann Oncol; 2016 Jun; 27(6):1047-1054. PubMed ID: 27029704
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.
Ettl J; Harbeck N
Expert Rev Anticancer Ther; 2017 Aug; 17(8):661-668. PubMed ID: 28649895
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib.
Bøttcher TM; Cold S; Jensen AB
Acta Oncol; 2019 Feb; 58(2):147-153. PubMed ID: 30375908
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
Battisti NML; Kingston B; King J; Denton A; Waters S; Sita-Lumsden A; Rehman F; Stavraka C; Kristeleit H; Sawyer E; Houghton D; Davidson N; Howell S; Choy J; Harper P; Roylance R; Fharat R; Mohammed K; Ring A; Johnston S
Breast Cancer Res Treat; 2019 Apr; 174(3):731-740. PubMed ID: 30656459
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
Hoste G; Punie K; Wildiers H; Beuselinck B; Lefever I; Van Nieuwenhuysen E; Han SN; Berteloot P; Concin N; Salihi R; Vergote I; Neven P
Breast Cancer Res Treat; 2018 Aug; 171(1):131-141. PubMed ID: 29766363
[TBL] [Abstract][Full Text] [Related]
14. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Chirila C; Mitra D; Colosia A; Ling C; Odom D; Iyer S; Kaye JA
Curr Med Res Opin; 2017 Aug; 33(8):1457-1466. PubMed ID: 28463012
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib: first global approval.
Dhillon S
Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
[TBL] [Abstract][Full Text] [Related]
16. Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer.
Wilkie J; Schickli MA; Berger MJ; Lustberg M; Reinbolt R; Noonan A; Ramaswamy B; Sardesai S; VanDeusen J; Wesolowski R; Williams N; Stover DG; Li J; Vargo CA
Clin Breast Cancer; 2020 Feb; 20(1):33-40. PubMed ID: 31451366
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
Freedman RA; Tolaney SM
Breast Cancer Res Treat; 2018 Feb; 167(3):607-614. PubMed ID: 29103175
[TBL] [Abstract][Full Text] [Related]
18. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
Kish JK; Ward MA; Garofalo D; Ahmed HV; McRoy L; Laney J; Zanotti G; Braverman J; Yu H; Feinberg BA
Breast Cancer Res; 2018 May; 20(1):37. PubMed ID: 29720233
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R
Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Niraula S; Ocana A
Cancer Treat Rev; 2016 Nov; 50():168-174. PubMed ID: 27693931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]